References
1. Sobin, L. H.; Gospodarowicz, M. K.; Wittekind, C. H.. TNM classification of malignant tumors. 7th ed. West Sussex, UK: John Wiley & Sons; 2009.
2. Tanaka, K. 2020. IV. Treatment of unresectable cases-immune checkpoint inhibitor. Gan To Kagaku Ryoho Cancer & Chemotherapy 47:1050-54.
3. Kiyota, N., Hasegawa, Y., Takahashi, S., Yokota, T., Yen, C.J., Iwae, S., et al. 2017. A randomized, open-label, Phase Ⅲ clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncology 73:138-146.
4. Hanamure, Y., Hayashi, T., Takaki, M., Ito, K. 2019. Response to salvage chemotherapy after progression on nivolumab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Japanese Journal of Head and Neck Cancer 45:41-45.
5. Park, S.E., Lee, S.H., Ahn, J.S., Ahn, M.J., Park, K., Sun, J.M. 2018. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 13:106-111.
6. Schvartsman, G., Peng, S.A., Bis, G., Lee, J.J., Benveniste, M.F.K., Zhang, J., et al. 2017. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112:90-95.
7. Ogawara, D., Soda, H., Iwasaki, K., Suyama, T., Taniguchi, H., Fukuda, Y., et al. 2018. Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy. Thoracic Cancer 9:175-180.
8. Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., et al. 2012. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Annals of Oncology 23:2313-2318.
9. Aparicio, S., Caldas, C. 2013. The implications of clonal genome evolution for cancer medicine. New England Journal of Medicine 368:842-851.
10. Ueda, M., Rin, S., Niiyama, T., Hata, H., Imamachi, K. 2018. Collaboration in medical treatment to use Nivorumab against oral cancer, Clinical Oncologist and Oral and Maxillofacial surgeon. Journal of Japanese Society of Oral Oncology 30:135-143.
11. Jackaman, C., Majewski, D., Fox, S.A., Nowak, A.K., Nelson, D.J. 2012. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo. Cancer Immunology, Immunotherapy 61:2343-2356.
12. Shurin, G.V., Tourkova, I.L., Kaneno, R., Shurin, M,R. 2009. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. Journal of Immunology 183:137-144.
13. Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., et al. 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Reserach 70:3052-3061.